HKPD

Cellyan Biotechnology Co., Ltd (HKPD) Risks & Opportunities Analysis (2026)

Invetso Score: 7.8/10 — Strong · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Risks

Score: 7.4 (Strong)

Long receivable collection at 103 days versus peers typically implies slower cash realization, which can pressure working capital efficiency and limit growth flexibility.

Cash conversion cycle of 67 days versus leaner peer models suggests more capital tied up in operations, reducing resilience if demand softens or pricing weakens.

Negative interest coverage versus profitable peers indicates current earnings do not cover financing costs, which can constrain margin recovery and amplify downside in a higher-rate environment.

Despite low debt-to-equity and negative net debt, the company’s liquidity profile is stronger than leveraged peers, limiting refinancing risk and moderating balance-sheet downside.

Inventory days near 11 and current ratio above 3.8 compare favorably with peers, reducing near-term supply-chain and liquidity risk relative to more stretched operators.

Opportunities

Score:

Net cash position versus indebted peers provides greater capacity to fund working capital and absorb volatility, supporting more stable execution through the cycle.

High current and quick ratios versus peers indicate ample short-term liquidity, which can support customer terms, inventory availability, and share gains in tighter markets.

Low inventory days versus peers suggest efficient stock management, which can improve service levels and reduce obsolescence risk as demand patterns shift.

Negative net debt versus leveraged competitors creates optionality for selective investment or pricing support, potentially strengthening positioning if industry conditions remain uneven.

Overall Score

Score:

HKPD shows strong liquidity and a net cash balance versus peers, but slower receivables and negative interest coverage temper the forward outlook by constraining cash conversion and earnings resilience.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Cellyan Biotechnology Co., Ltd. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →